OBJECTIVES: This study sought to determine the prevalence and determinants of use of recommended antiretroviral regimens among urban seropositive men who have sex with men (MSM). METHODS: A probability telephone sample of MSM was taken within regions of Chicago, Los Angeles, New York, and San Francisco. Analysis focused on use of antiretroviral therapies. RESULTS: Although the majority of seropositive MSM with CD4 counts below 500 per microliter were using recommended antiretroviral regimens, 26% of seropositive MSM were not receiving such care. Men who were younger, who reported a sexual orientation other than homosexual, who had a more recent interview date, who were at middle levels of affiliation with the gay community, and who reported higher levels of perceived exclusivity on the part of the gay community were less likely to be using recommended antiretroviral regimens. CONCLUSIONS: Although current efforts to make antiretroviral therapies available to HIV-seropositive MSM are reasonably effective, additional efforts are needed for MSM characterized by relative youth and lower social support.
OBJECTIVES: This study sought to determine the prevalence and determinants of use of recommended antiretroviral regimens among urban seropositive men who have sex with men (MSM). METHODS: A probability telephone sample of MSM was taken within regions of Chicago, Los Angeles, New York, and San Francisco. Analysis focused on use of antiretroviral therapies. RESULTS: Although the majority of seropositive MSM with CD4 counts below 500 per microliter were using recommended antiretroviral regimens, 26% of seropositive MSM were not receiving such care. Men who were younger, who reported a sexual orientation other than homosexual, who had a more recent interview date, who were at middle levels of affiliation with the gay community, and who reported higher levels of perceived exclusivity on the part of the gay community were less likely to be using recommended antiretroviral regimens. CONCLUSIONS: Although current efforts to make antiretroviral therapies available to HIV-seropositive MSM are reasonably effective, additional efforts are needed for MSM characterized by relative youth and lower social support.
Authors: C C Carpenter; M A Fischl; S M Hammer; M S Hirsch; D M Jacobsen; D A Katzenstein; J S Montaner; D D Richman; M S Sáag; R T Schooley; M A Thompson; S Vella; P G Yeni; P A Volberding Journal: JAMA Date: 1996-07-10 Impact factor: 56.272
Authors: D W Cameron; M Heath-Chiozzi; S Danner; C Cohen; S Kravcik; C Maurath; E Sun; D Henry; R Rode; A Potthoff; J Leonard Journal: Lancet Date: 1998-02-21 Impact factor: 79.321
Authors: S M Hammer; K E Squires; M D Hughes; J M Grimes; L M Demeter; J S Currier; J J Eron; J E Feinberg; H H Balfour; L R Deyton; J A Chodakewitz; M A Fischl Journal: N Engl J Med Date: 1997-09-11 Impact factor: 91.245
Authors: R M Gulick; J W Mellors; D Havlir; J J Eron; C Gonzalez; D McMahon; D D Richman; F T Valentine; L Jonas; A Meibohm; E A Emini; J A Chodakewitz Journal: N Engl J Med Date: 1997-09-11 Impact factor: 91.245
Authors: D H Osmond; J Catania; L Pollack; J Canchola; D Jaffe; D MacKellar; L Valleroy Journal: J Acquir Immune Defic Syndr Date: 2000-08-01 Impact factor: 3.731
Authors: S A Strathdee; A Palepu; P G Cornelisse; B Yip; M V O'Shaughnessy; J S Montaner; M T Schechter; R S Hogg Journal: JAMA Date: 1998-08-12 Impact factor: 56.272
Authors: Ron Stall; Thomas C Mills; John Williamson; Trevor Hart; Greg Greenwood; Jay Paul; Lance Pollack; Diane Binson; Dennis Osmond; Joseph A Catania Journal: Am J Public Health Date: 2003-06 Impact factor: 9.308
Authors: Jeffrey A Kelly; Janet S St Lawrence; Yuri A Amirkhanian; Wayne J DiFranceisco; Michelle Anderson-Lamb; Luis I Garcia; Manh T Nguyen Journal: AIDS Educ Prev Date: 2013-02
Authors: Travis C Porco; Jeffrey N Martin; Kimberly A Page-Shafer; Amber Cheng; Edwin Charlebois; Robert M Grant; Dennis H Osmond Journal: AIDS Date: 2004-01-02 Impact factor: 4.177